Jinling Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 13.5yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Jinling Pharmaceutical Company Limited (SZSE:000919)
Dec 24
We Believe That Jinling Pharmaceutical's (SZSE:000919) Weak Earnings Are A Good Indicator Of Underlying Profitability
Nov 04Earnings Troubles May Signal Larger Issues for Jinling Pharmaceutical (SZSE:000919) Shareholders
May 06CEO
Jinling Pharmaceutical has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| VP, Chief Accountant & Non-Independent Director | no data | CN¥755.40k | 0.039% CN¥ 1.7m | |
| VP & Non-Independent Director | no data | CN¥959.90k | 0.050% CN¥ 2.1m | |
| Chief Economist | no data | CN¥699.70k | 0.029% CN¥ 1.2m | |
| Chief Engineer | no data | CN¥747.50k | 0.029% CN¥ 1.2m | |
| VP & Non-Independent Director | 5.7yrs | CN¥761.40k | 0.027% CN¥ 1.2m | |
| Secretary | 26.3yrs | CN¥433.40k | 0.027% CN¥ 1.1m | |
| Assistant to President | no data | CN¥630.60k | 0.026% CN¥ 1.1m | |
| General Manager Assistant | no data | CN¥522.50k | 0.016% CN¥ 677.9k | |
| Executive Vice President | 13.5yrs | CN¥141.40k | no data |
13.5yrs
Average Tenure
53.5yo
Average Age
Experienced Management: 000919's management team is seasoned and experienced (13.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| VP, Chief Accountant & Non-Independent Director | 1.5yrs | CN¥755.40k | 0.039% CN¥ 1.7m | |
| VP & Non-Independent Director | 4.5yrs | CN¥959.90k | 0.050% CN¥ 2.1m | |
| VP & Non-Independent Director | 1.5yrs | CN¥761.40k | 0.027% CN¥ 1.2m | |
| Non-Employee Supervisor | 1.5yrs | no data | no data | |
| Chairman of the Supervisory Board | 7.5yrs | no data | no data | |
| Independent Director | 4.5yrs | CN¥100.00k | no data | |
| Independent Director | 4.5yrs | CN¥100.00k | no data | |
| Non-Employee Supervisor | 4.5yrs | no data | no data | |
| Non-independent Director | 1.5yrs | no data | no data | |
| Non-Independent Director | 1.5yrs | no data | no data | |
| Independent Director | 1.5yrs | CN¥50.00k | no data | |
| Employee Supervisor | 1.5yrs | no data | 0.011% CN¥ 474.5k |
1.5yrs
Average Tenure
50yo
Average Age
Experienced Board: 000919's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 19:18 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jinling Pharmaceutical Company Limited is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jessica Li | BofA Global Research |
| Han Wei Yu | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Weina Jiang | Everbright Securities Co. Ltd. |